Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in Allogeneic Transplantation for AML and MDS
NCT07737769Phase 1Not yet recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Nov 2026
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of arsenic trioxide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Incidence of dose limiting toxicities at 35 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
arsenic trioxide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07737769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07737769.